Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
- Posted on June 6, 2026
- By Bing News
- 0 Views
- 1 min read
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
NEW YORK, June 6 (Reuters) - Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss and helping knee pain. • In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults
